| Ytd | -23.66% | |
| 1y | -11.31% |
| Open | 4.13 | Prev Close | 4.13 | Low | 4.00 | High | 4.35 | Mkt Cap | 383.32M |
| Vol | 1.71M | Avg Vol | 1.44M | EPS | -1.08 | P/E | N/A | Forward P/E | -3.22 |
| Beta | 0.14 | Short Ratio | 14.48 | Inst. Own | 58.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.20 | 200-d Avg | 5.32 | 1yr Est | 14.29 |
ZURA News
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotech
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both sm
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clini
Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the pri
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price
Zura Bio Limited (Nasdaq: ZURA) (âZuraâ), a clinicalâstage biotechnology company developing no
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst conse
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotech
Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have received an average rating of "Mode
Zura Bio Limited (NASDAQ: ZURA - Get Free Report)'s share price rose 5.3% during trading on Friday.
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-do
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical deve
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotech
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clini
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotech
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.22) per share which missed the analyst conse
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotech
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clini
https://www.sec.gov/ix?doc=/Archives/edgar/data/1855644/000110465926047784/tm2612540d1_8k.htm
U.S. stock futures fall around 250 points on Monday. ASTS shares drop 13.5% after satellite placed i
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been assigned an average rating of "Moderate B
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given a consensus rating of "Moderate Buy
Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.49) per share which missed the analyst conse
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-st
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday. Fo
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s p